Latest Pharmaceutical Pricing News

Page 1 of 1
Cardinal Health has lifted its fiscal 2027 earnings outlook after a strong opening quarter, with revenue reaching US$67.5 billion and non-GAAP diluted EPS rising 28%. The healthcare distributor also completed a US$500 million share repurchase and advanced several strategic initiatives.
Ada Torres
Ada Torres
5 Nov 2026
Adheris Health has achieved cashflow break-even in Q4 FY26 following a strategic reset focused on its US operations, cutting costs by over 30% and repositioning for growth in FY27 with a stronger digital pipeline.
Ada Torres
Ada Torres
31 Aug 2026
Botanix Pharmaceuticals has clarified that recent share price movements are linked to a rumored US executive order on drug pricing, confirming no undisclosed material information. The company reassures investors of compliance with ASX disclosure rules amid market speculation.
Ada Torres
Ada Torres
12 May 2025
Botanix Pharmaceuticals clarifies its lead product Sofdra is unlikely to face price cuts under the proposed US executive order on drug pricing, citing its exclusive US market approval and distinct formulations abroad.
Ada Torres
Ada Torres
12 May 2025

Browse the archive

Full archive